Skip to Content

Zanubrutinib Approval Status

FDA Approved: No
Generic name: zanubrutinib
Company: BeiGene, Ltd.
Treatment for: Mantle Cell Lymphoma

Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor in development for the treatment of patients with mantle cell lymphoma (MCL).

Development Status and FDA Approval Process for zanubrutinib

DateArticle
Aug 21, 2019BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Dec  1, 2018BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide